#China #Suzhou #RNA Therapeutics #Qiming Venture Partners #Vivatides Therapeutics

Vivatides Therapeutics Announces Major Funding to Revolutionize RNA Therapeutics

In a significant development for the field of RNA therapeutics, Vivatides Therapeutics has announced the closure of an oversubscribed Series A financing round raising $54 million. This global biotechnology company, headquartered in Suzhou, China, is dedicated to pioneering extrahepatic RNA-targeting therapeutics, a promising area in medical science that aims to extend therapeutic applications beyond the liver.

The financing was co-led by Qiming Venture Partners and a prominent industry fund, with additional participation from Highlight Capital and TF Capital. Notably, Apricot Capital, an existing investor, renewed its commitment by contributing further investment. The funds raised from this financing round are earmarked for advancing Vivatides' cutting-edge extrahepatic delivery platform, propelling various pipeline programs into clinical development, and enhancing the company’s global workforce and research and development (R&D) network.

Founded in 2025, Vivatides has already made notable strides in the RNA therapeutics landscape. Achieving both seed and Series A investment within less than a year of its inception, the company has demonstrated impressive investor confidence in its innovative technology and operational proficiency.

RNA therapeutics are touted as the next major funding modality, promising significant benefits due to their high specificity and lasting efficacy. However, one prevailing limitation has been their traditional reliance on liver-targeting applications due to delivery challenges. This limitation leaves a vast array of diseases involving extrahepatic tissues significantly underserved, presenting an immense opportunity for innovation.

With the emergence of advanced extrahepatic delivery technologies, RNA-based treatments are now on the verge of expansion into broader areas, including chronic conditions such as hyperlipidemia, hypertension, and cancer, thus unlocking extensive market potential.

Vivatides’ experienced leadership boasts a robust background within leading RNA therapeutics firms. The management team includes experts who have played pivotal roles in the progression of numerous successful extrahepatic RNA programs toward clinical trials. Leveraging this wealth of experience, Vivatides has cultivated a unique extrahepatic delivery platform with capabilities covering both small interfering RNA (siRNA) and antisense oligonucleotides (ASO). The company has achieved considerable progress in various aspects such as ligand conjugation, delivery efficiency, targeting specificity, and safety, all of which have been validated by encouraging in vivo results.

“Extrahepatic delivery is the key that will unlock RNA therapeutics from niche rare diseases to broad chronic indications,” expressed Keming Zhou, Founder of Vivatides Therapeutics. “We are honored to have garnered the support and recognition of distinguished investors. This financing will expedite our platform's evolution and pipeline advancement, paving the way for innovative RNA therapies that address extrahepatic disease areas. We aim to engage more long-term, value-driven partners to deliver transformative therapies worldwide.”

Dr. Kan Chen, a Partner at Qiming Venture Partners, highlighted, “We have always been optimistic about the potential of small nucleic acid drugs across various disease areas. Progress in extrahepatic targeting technologies is broadening clinical frontiers. Vivatides has showcased solid technical expertise and efficient execution capabilities, accomplishing notable milestones with its platform. We are eager to see it continue driving technological breakthroughs and accelerating the clinical translation of its pipeline.”

Following this funding, Vivatides intends to expedite preclinical optimizations and Investigational New Drug (IND)-enabling studies while expanding its R&D and management teams. The focus remains on addressing unmet medical needs prevalent among extrahepatic diseases, with an aspiration to emerge as a leader in RNA therapeutics and furnish patients globally with safer and more effective treatment options.

As the company gears up for its next journey, the healthcare landscape may soon witness the transformative power of Vivatides’ innovations in RNA therapeutics, reshaping treatment paradigms across a multitude of diseases.